RAPID Moves CMS Into Your Pivotal Trial Design

The coverage pathway pulls Medicare evidence expectations into the investigational stage. For device innovators, coverage stops being a post-approval problem and potentially a trial design decision.

By Tim Sheflin with Naghmeh Nouri contributing.

The August 7, 2026, joint press release from the FDA and CMS introducing the Transformed Approval Roadmap for Innovative Devices (RAPID) coverage pathway, tailored for Breakthrough Device Designation (BDD) technologies, has renewed momentum toward solving a longstanding industry challenge: two interrelated agencies with distinct mandates operating independently (or in silo).

While the FDA focuses on establishing "Safety and Effectiveness," CMS operates under a broader Congressional mandate: prohibiting payment for items or services that are not "reasonable and necessary for the diagnosis or treatment of illness or injury." RAPID does not represent the respective agencies’ first (or likely last) attempt to bridge the divide in evidence expectations, but each attempt provides insight into the type of data that resonates with the distinct stakeholders.

The Focus on Outcomes

A Federal Register Notice seeking public comment on the RAPID proposal highlights a pivotal concept that distinguishes CMS from the FDA: health outcomes. The notice states that CMS and the FDA "believe that the RAPID coverage pathway can address the gap by providing manufacturers with information on the specific health outcomes needed to support Medicare National Coverage Determinations (NCDs) much earlier in the process."

The core mechanism of RAPID relies on leveraging Investigational Device Exemption (IDE) pivotal studies that embed the specific outcome measures CMS requires for coverage. However, the notice also signals that CMS may still apply Coverage with Evidence Development (CED) within an NCD, potentially committing manufacturers to post-market clinical outcomes studies for years after initial FDA clearance or approval.

This shifts the strategic burden directly onto medical device leaders:

• Are manufacturers prepared to integrate CMS-focused health outcomes into early regulatory trial designs?
• Will CMS leverage payment mechanisms for RAPID technologies that adequately compensate for that larger upfront investment?

CMS leadership has acknowledged the longstanding goal of aligning these parallel pathways earlier in the development lifecycle. Few manufacturers, patient advocates, or health systems would argue with that intent. In fact, most device companies face this exact dynamic internally when balancing budget allocations between R&D, regulatory, market access, and commercialization.

Strategic Evidence Generation Pre- and Post-RAPID

Technologies rarely succeed or fail on clinical merit alone. Long-term commercial adoption hinges on an innovator’s ability to execute an evidence strategy that satisfies key stakeholders: FDA, CMS, commercial payers, health systems, clinicians, and patients alike.

Whether utilizing the RAPID pathway or traditional routes, core strategic questions remain:

1. Pivotal Trial Scope: Can a single trial design satisfy both regulatory and reimbursement endpoints without becoming cost-prohibitive or overly complex?
2. Evidence Sequencing: If a single trial is not feasible, how should pre-market and post-market evidence (e.g., real-world evidence, registries) be phased efficiently?
3. Investor Alignment: How do you articulate the value of higher upfront trial costs to investors when the tradeoff is bridging the "valley of death" between approval and coverage?

Editor’s note: CMS is accepting public comments on the proposed procedural notice until Oct. 13, 2026. With TCET paused for new candidates, RAPID would become CMS's primary accelerated coverage pathway for eligible Breakthrough Devices. Electronic comments can be submitted via the Federal Regulations Docket.

RAPID Will Not / Does Not Lower Evidence Expectations

If your new medical device or technology is evaluating RAPID’s potential to impact your development and/or coverage pathway, ensure that you are planning with the end in mind, not just the first barrier to market entry. Understand that nothing communicated about RAPID indicates that the FDA or CMS will lower their evidence expectations, so be sure to confirm that the investment in studies will have the intended impact. Identify partners that can help avoid the pitfalls of trial designs that are intended to please everyone, but still fall below the statutory responsibilities of CMS and the FDA.

How Veranex Navigates the Alignment Gap

Addressing these challenges requires Integrated Evidence Planning (IEP): a cross-functional strategy that aligns regulatory, clinical, health economics, and real-world data streams into a single, adaptive roadmap. By unifying expertise across Product Design, Regulatory Affairs, Clinical Operations, HEOR, Reimbursement, and Commercial Strategy, Veranex helps medical device innovators bridge capability gaps, optimize trial design, and streamline the journey from regulatory clearance to widespread market adoption.

Partner with Veranex’ CSMA Practice 

At Veranex CSMA, we help medical device manufacturers navigate complex reimbursement transformations through integrated evidence planning, market access strategy, and health economics modeling. Our team combines deep Medicare policy expertise with practical implementation experience, helping you build the infrastructure needed to thrive under WISeR and similar emerging models. 

The companies that act now (adjusting strategies, building support systems, and generating appropriate-use evidence) will maintain market leadership. Those that wait risk being blindsided as demonstration projects become permanent policy.